Table 1.
Subjects enrolled in the study.
| Subject Number |
Weeds Gestation at Sample Collection | Age | Ethnicity | Natural Infection |
Latest COVID-I9 Vaccine |
|---|---|---|---|---|---|
| 1 | 10 | 35 | Hispanic/White | N | 12/2022, Moderna Bivalent |
| 2 | 24 | 34 | Non-hispanic/White | Y | 1/2023, Moderna Bivalent |
| 3 | 25 | 35 | Non-hispanic/White | N | 12/2022, Pfizer Bivalent |
| 4 | 27 | 28 | Non-hispanic/White | N | 12/2022, Moderna Bivalent |
| 5 | 19 | 39 | Non-hispanic/White | Y | 1/2023, Pfizer Bivalent |
| 6 | 17 | 40 | Non-hispanic/White | N | 12/2022, Moderna Bivalent |
| 7 | 26 | 36 | Non-hispanic/White | N | 12/2022, Pfizer Bivalent |
| 8 | 17 | 31 | Non-hispanic/White | N | 1/2023, Pfizer Bivalent |
| 9 | 20 | 31 | Non-hispanic/White | N | 2/2023, Pfizer Bivalent |
| 10 | 23 | 28 | Non-hispanic/White | Y | 2/2023, Pfizer Bivalent |
| 11 | 16 | 28 | Non-hispanic/Cancasian and Asian | N | 1/2023, Moderna Bivalent |
| 12 | 26 | 34 | Non-hispanic/White | N | 2/2023, Moderna Bivalent |
| 13 | 26 | 42 | Non-hispanic/White | N | 4/2023, Pfizer Bivalent |
| 14 | 23 | 30 | Non-hispanicWhite | N | 5/2023, Moderna Bivalent |
| 15 | 34 | 32 | Non-hispanic/White | N | 8/2023, Pfizer Bivalent |
| 16 | 24 | 32 | Non-Hispanic/Asian | Y | 9/2023, Pfizer Bivalent |
| 17 | 23 | 37 | Non-hispanic/White | Y | 9/2023, Pfizer Bivalent |
| 18 | 21 | 34 | Non-hispanic/White | Y | 10/2023, Moderna |
| 19 | 8 | 40 | Non-hispanic/White | Y | 9/2023, Moderna |